Purpose: To determine whether the maximum standardized uptake value (SUV) of [
Introduction
Lung cancer is the leading cause of cancer death, having caused an estimated 1.18 million deaths worldwide in 2002 [1] . Although current treatment strategies do not cure most patients, there have been improvements in the outcome over time. Definitive radiotherapy (RT) is the main treatment modality for medically inoperable or locoregionally advanced non-small-cell lung cancer (NSCLC). Nevertheless, in the cases of advanced disease, more than 90% of patients die from the disease [2] ; therefore, there is a need to identify a subset of NSCLC patients with longer life expectancies. Clinicopathologic features of NSCLC have been studied, but are not commonly used in prediction and stratification of patients' prognosis, with the exception of stage and performance status [3, 4] . www.e-roj.org http://dx.doi.org/10.3857/roj.2013.31. 3.111 During the last decade, [ 18 F]fluorodeoxyglucose positron emission tomography (FDG PET), which is based on differences in glucose metabolism between tumor and normal tissue, has been incorporated into the cancer management process, for staging [5] [6] [7] [8] , estimation of treatment response [9] [10] [11] [12] [13] [14] , and delineation of RT targets [15] for NSCLC. In addition, a review of 13 studies found that the maximum standardized uptake value (maxSUV) of the primary tumor has a prognostic value in NSCLC [16] . In spite of some debates with regard to the role of FDG PET as a prognostic factor [17, 18] , it is widely accepted that maxSUV on FDG PET is a significant prognostic factor. However, maxSUV of primary tumor has some limitation because tumors usually demonstrate heterogeneity in biological and metabolic characteristics with progression or metastasis. Especially, the characteristics of metastatic cancer cells are crucial because they are more closely correlated with prognosis, after treatment of primary lesions. Therefore, biological and metabolic characteristics of metastatic lesions are recommended to be considered in prognostication.
Although the histology of mediastinal lymph nodes is crucial in the treatment strategy, FDG PET is becoming more useful in mediastinal staging of the lung cancer. In one study, an unique concept was proposed that a ratio between the maxSUV of the tumor and the lymph nodes predicts nodal pathology in patients with NSCLC [19] . Moreover a generation of the metabolic ratio may take into account the different techniques and circumstances used in a scanning of patients. At this finding we hypothesized that the metabolic ratio of NSCLC could be a better prognostic predictor of lung cancer, than metabolic activity of the tumor or the lymph node. To verify this hypothesis, two parameters for metabolic activity of lymph nodes were adopted for analysis; maxSUV of lymph node and ratio of maxSUV between primary lesion and lymph node.
Materials and Methods

Patients
The medical records of 70 consecutive NSCLC patients who were treated with definitive RT at our institution from October 2004 to December 2008 were retrospectively reviewed. Patients with suspicious lymph node disease and absence of M1a and M1b metastatic disease formed the study group. Patients with recurrent tumors were excluded. Pretreatment evaluation consisted of history taking and physical examination, contrastenhanced chest computed tomography (CT), FDG PET/PET-CT scan, and pulmonary function test. No patients were staged with mediastinoscopy, and lymph nodes were considered suspicious for metastatic disease if the short axis diameter was larger than 1 cm on chest CT or metabolically active. There were 7 patients with a lymph node sized 1 cm or smaller, and the maxSUV of these nodes ranged 3 to 22. At final, 68 patients were included in the final analysis, because 2 patients were excluded from analysis due to uncertain histology. All patients were staged using the American Joint Committee on Cancer (6th edition) TNM system.
Positron emission tomography
The time intervals between PET or PET-CT and initial treatment were less than 8 weeks. Before FDG PET scans, patients fasted for at least 6 hours. Using dedicated PET or PET-CT scanners (ECAT EXACT47 and Biograph 40, Siemens, Malvern, PA, USA; GEMINI, Philips Medical Systems, Cleveland, OH, USA), images were acquired from the skull base to the upper thigh 60 minutes after 5.18 MBq/kg (0.14 mCi/kg) of FDG administration. Most of patients (64 of 68) underwent PET-CT and only 4 patients underwent PET only. Images were reconstructed using iterative reconstruction algorithms (3D row-action maximum-likelihood algorithm and ordered subset expectation maximization). Region of interests (ROIs) were drawn over main masses on trans-axial images, and standard uptake values (SUVs) were calculated using the following equation: ROI tissue activity concentration × lean body mass / injected dose. Maximal uptakes of primary tumor and lymph node were presented as maxSUV P and maxSUV LN , respectively. The maxSUV of a given subject in the present study represents the highest maxSUV of the whole subject lesions. All the images were reviewed by two experienced nuclear medicine physicians. After the maxSUV P and maxSUV LN were obtained, the ratio between them was calculated as maxSUV LN to maxSUV P , which was coined as mSUVR.
Treatment
After the FDG PET study and a definitive diagnosis, 43 patients (63%) were treated with concurrent chemoradiotherapy, 21 patients (31%) were treated with neoadjuvant chemotherapy before RT, 16 patients (24%) were treated with chemotherapy after RT, and 14 patients (21%) were treated with RT only due to old age (n = 12) and comorbidity (n = 2). Platinum-based multi-drug regimens were administered to most patients.
All patients were treated with involved-field RT, once a day, 5 days a week, and a total dose of 60 to 66 Gy with CT planning.
www.e-roj.org The gross tumor volume (GTV) consisted of all known sites of disease defined by CT with the visual aid of FDG PET or PET-CT scan data, without inclusion of elective nodal targets. The clinical target volume was determined from the GTV with an automatic expansion of 1 cm. The planning target volume included the physiologic motion and respiratory movement, which ranged from 1 to 2 cm. Critical normal structures were also contoured. Almost all patients were treated with conventional fractionation (1.8 to 2.0 Gy) without a planned treatment break, and only 3 patients were treated with hypofractionation (4 Gy) for poor performance and comorbidity.
Statistical analysis
Survival status was evaluated in November 2012. Distant metastasis was defined as an appearance of disease at other than the primary site or regional lymph nodes. Metastases to any organs, such as the brain, bone, adrenal glands, contralateral or ipsilateral lung (in a different lobe) were considered distant metastasis, and nodal stations other than the mediastinal and the intrapulmonary nodal chain as nonregional stations. All events observed by not only radiological but clinical or physical examinations were considered significant. Distant metastasis-free survival (DMFS) and overall sur vival (OS) rates were calculated by use of the product-limit method of Kaplan-Meier. All estimates were calculated from the date of pathologic diagnosis until the defined event, if any, or until the last contact or death. Patients were censored at the time of last follow-up. The log-rank test was used for assessment of the equality of the survivor across groups. The Cox proportional hazards model was used for multivariate analysis to assess the effect of patients' characteristics and other prognostic factors of significance, including the maxSUV of the primary tumor and lymph node and the mSUVR, on the end points. All tests were two tailed, with p < 0.05 considered statistically significant. SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) was used for all analyses.
Results
Median follow-up from the date of diagnosis in all patients was 20 months (range, 4.2 to 84.6 months) with a median follow-up among survivors of 42 months (range, 14.7 to 84.6 months). No patient was lost to follow-up; median OS for the entire patient population was 21.3 months.
The median maxSUV of the primary tumor and the lymph node was 10.3 (range, 2.1 to 26.3) and 6.6 (range, 0 to 21.9), respectively. The short axis diameter of five lymph nodes with maxSUV < 3 ranged from 1.5 to 2.6 cm. Seven patients (10%) had metabolically active but normal sized nodes. The median mSUVR was 0.63 (range, 0 to 1). We performed sensitivity analyses in order to determine the mSUVR value that best differentiated patients into subgroups of prognosis, and the value of 0.9 was the most discriminative cutoff mSUVR value for OS (Fig. 1) .
The median OS of 50 patients (74%) with mSUVR ≤ 0.9 was 26 months (95% confidence interval [CI], 19 to 32 months). The median OS of 18 patients (26%) with mSUVR > 0.9 was 11 months (95% CI, 6 to 16 months). The median DMFS of patients with mSUVR ≤ 0.9 and patients with mSUVR > 0.9 was 30 months (95% CI, 13 to 46 months) and 11 months (95% CI, 5 to 17 months), respectively. Survival differences between the two groups were statistically significant in OS (p = 0.01), but not statistically significant in DMFS (p = 0.29).
Multivariate analysis was performed, in which age, performance status, stage, and use of chemotherapy during RT were considered in addition to the maxSUV and the cutoff mSUVR.
As a continuous variable, the mSUVR and the maxSUVs of the primary tumor and the lymph node were not correlated with OS (Table 1) . However, in categorical method, patients with mSUVR > 0.9 were associated with a 1.85-fold increase in the risk of death compared to those with mSUVR ≤ 0.9, and it is statistically significant (hazard ratio [HR] = 1.85; p = 0.05). Another significant association was observed between performance status and OS (HR = 2.22; p = 0.05). Details of the multivariate models are found in Table 2 . Combining the two stratification variables, the 2-year OS for patients were as follows: with both good performance (Eastern Cooperative Oncology Group [ECOG] ≤ 1) and mSUVR ≤ 0.9, 71%; with either poor performance (ECOG > 1) or mSUVR > 0.9, 23% (p = 0.04) (Fig. 2) . Only 4 patients had poor performance status and disease with high mSUVR, and all died before 2 years from the end of RT. The statistical difference among 3 groups, divided by the number of risk factors (poor performance and high mSUVR), was significant in OS (p = 0.001). There was no difference between two groups divided by mSUV = 0.9, in patient characteristics (Table 3) , and the median maxSUV for disease was not different between two groups (10.3 for each ones).
Discussion and Conclusion
In the present study, we found that pretreatment mSUVR is a strong and independent prognostic predictor for OS in patients treated with definitive RT for lymph node positive NSCLC. When clinical cutoff value was used, patients with mSUVR ≤ 0.9 had longer OS than patients with mSUVR > 0.9. These findings are consistent with previously published data, advocating the prognostic role of FDG PET [16, 20, 21] . However, this study is the first to demonstrate that a metabolic activity of lymph The maximal SUV ratio (mSUVR) was used for model formation as a categorical variable. OS, overall survival; DMFS, distant metastasis-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CCRT, concurrent chemotherapy and radiotherapy.
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The maximal SUV of primary tumor on FDG PET has significant predictive value, and it can demonstrate the metabolic activity and aggressiveness of primary tumor. But it has some limitation because tumor cells usually show heterogeneity with progression, and especially, with metastasis. If there is no evidence of gross distant metastasis and the primary lesions are successfully treated like in this study, the prognosis of the patients is critically affected by characteristics of metastatic cells. The metabolic activity of metastatic lymph node can be a surrogate indicator for characteristics of metastatic cells.
For this purpose, we adopted two parameters for metabolic activity of lymph nodes; maxSUV LN and mSUVR. As lymph nodes may show variable metabolic activity due to benign reactive activation due to cancer and inflammation, mSUVR may be a better parameter than maxSUV LN . With similar concept, mSUVR has been suggested as a diagnostic parameter for lymph node metastasis. In a retrospective review of a prospective database, Cerfolio and Bryant [19] evaluated the clinical utility of the ratio of the maxSUV of the mediastinal lymph node to the maxSUV of the primary tumor in patients with NSCLC. The median ratio of malignant lymph nodes was 0.58, and the authors found that a ratio of 0.56 or greater was predictive of lymph node malignancy with 94% sensitivity and 72% specificity.
Metabolic activity of NSCLC is known to have a correlation with tumor aggressiveness, due to its intrinsic relation with tumor doubling time [22] and proliferation rates [23, 24] . How then can it be explained that the metabolic ratio of the lymph node to the primary tumor has a prognostic value in NSCLC? First, as mentioned above, the mSUVR may be a predictor of nodal malignancy. The routine mediastinal biopsy is not mandatory for every lung cancer patients in our hospital. Although invasive techniques provide additional information in microscopic examination of cancer cells, recent innovation of non-invasive methods such as FDG PET gives insights to physicians to the consideration of 'risk-benefit ratio' . Second, we regarded the mSUVR as a relative activity of nodal disease and a capacity of disease for dissemination out of the nodal station. Thus, patients with a high mSUVR were expected to have a high risk of out-field nodal recurrence, an isolated recurrence outside of the radiation field. However, only 1 patient (6%) with mSUVR > 0.9 and 3 patients (6%) in the group with mSUVR ≤ 0.9 developed out-field nodal recurrence. These rates seem to be reasonable when considering a recent report from Memorial Sloan-Kettering Cancer Center, in which only 9% of patients had suffered from unexpected nodal recurrence without elective nodal RT [25] . Also, there was no difference in distant failure between the two groups, and we found no statistically significant difference in locoregional failure-free survival either (p = 0.26, data not shown). Also, mSUVR for patients with out-field nodal recurrence were 0.44, 0.47, 0.53, and 1. Thus a high mSUVR does not provide a clue to out-field nodal recurrence, but it may be associated with intrinsic aggressiveness of disease. Our study has several limitations. First, it suffers from a retrospective nature. There may be a selection bias, and there was a small variation in systemic therapy as well. The most significant critique of this study may come from the differences of total cycles and/or timing of combined chemo-regimen. But, 43 of 68 patients were treated with concurrent chemoradiotherapy, and platinum-based multidrug regimens were infused weekly, such as docetaxel with cisplatin or gemcitabine with carboplatin. It is noteworthy that the use of the concurrent chemoradiotherapy did not prove to be a significant factor and the mSUVR was a stronger prognostic factor for OS. Second, histological confirmation of the metastatic sites was not performed in patients. And this may be weak point of the study for it is well-known that FDG accumulate in benign condition, such as granulomatous lymphadenitis. Third, our study included 6 patients with N1 disease. For evaluation of N1 status in NSCLC patients, FDG PET/CT has limited predictive value [26] . But, metabolic exam of N1 patients showed hypermetabolic activity (13.4 and 21.9 for 1-cm sized nodes), though the short axis length of lymph node of ranged from 1 to 2.1 cm.
An implication of our findings is that patients with high mSUVR might be candidates for more intensive therapy, such as chemoradiotherapy based on novel agents. Also, as high mSUVR is associated with a high risk of death, a period of close examination for disease is mandatory, especially when patients belong to a very high risk subgroup identified by the combination of high mSUVR and poor performance status.
In conclusion, in NSCLC, pretreatment mSUVR is prognostic of OS in patients treated with definitive RT for lymph node positive disease. This FDG PET parameter remained prognostic of OS when controlling for age, performance, stage, and use of chemotherapy. Although prospective studies with large numbers of cases or with longer follow-up are warranted for confirmation, we have demonstrated that the mSUVR is important aid for use in treatment decisions for patients with NSCLC.
